# Renal Pharmacology: RAAS Inhibitors and Renoprotective Therapy

**Level:** PA/Medical Student **Duration:** 60–90 minutes **Version:** 2026-02-12

------------------------------------------------------------------------

## Learning Objectives

By the end of this module, students will be able to:

1.  **Explain** the renin-angiotensin-aldosterone system (RAAS) anatomy and physiology
2.  **Classify** RAAS inhibitors by mechanism (ACEi, ARB, DRI, ARNI, MRA)
3.  **Compare** efficacy, side effects, and contraindications of RAAS inhibitors
4.  **Apply** RAAS inhibitor therapy in proteinuric kidney disease, hypertension, and heart failure
5.  **Monitor** renal function and electrolytes during RAAS inhibition
6.  **Identify** why dual/triple RAAS blockade failed in clinical trials
7.  **Integrate** newer agents (ARNI, finerenone) into modern renoprotective strategy

------------------------------------------------------------------------

## RAAS Physiology Review

### The Cascade

    Juxtaglomerular apparatus detects ↓ perfusion pressure / ↓ Na+ delivery
                            ↓
                Renin release from granular cells
                            ↓
            Angiotensinogen (hepatic) → Angiotensin I
                            ↓
        ACE (lung endothelium) → Angiotensin II
                            ↓
        AT1 receptor activation (kidney, vessels, heart)
                            ↓
        ↑ GFR (efferent vasoconstriction), ↑ Na+ reabsorption,
        ↑ sympathetic tone, ↑ aldosterone, ↑ vasopressin

### Physiologic Effects of Angiotensin II (AT1 Receptor)

| **Target** | **Effect** | **Relevance** |
|----|----|----|
| **Glomerulus** | ↑ Efferent vasoconstriction (\>afferent) | ↑ GFR, but reduces peritubular capillary hydrostatic pressure |
| **Proximal tubule** | ↑ Na⁺ reabsorption | Volume expansion |
| **Collecting duct** | ↑ Aldosterone secretion | K⁺ wasting, Na⁺ retention |
| **Sympathetic** | ↑ Norepinephrine | ↑ HR, ↑ contractility, vasoconstriction |
| **Adrenal** | ↑ Aldosterone synthesis | Hypokalemia risk |
| **Heart** | ↑ Myocardial hypertrophy | LV remodeling in HF |
| **Vessels** | ↑ Vasoconstriction, ↑ smooth muscle proliferation | Hypertension, arterial stiffness |

### Counter-Regulatory Mechanism: Bradykinin

- **ACE** (angiotensin-converting enzyme) is identical to **kininase II**
- Inhibiting ACE → ↑ bradykinin accumulation
- **Bradykinin effects:** ↓ vasoconstriction, ↑ nitric oxide, ↑ prostaglandins
- **Clinical manifestation:** ACEi cough (15–20% incidence) due to pulmonary bradykinin accumulation

------------------------------------------------------------------------

## ACE INHIBITORS (ACEi)

### Mechanism of Action

ACE inhibitors competitively block **angiotensin-converting enzyme**, preventing conversion of angiotensin I → angiotensin II. Result: ↓ Ang II-mediated efferent vasoconstriction, ↓ aldosterone, ↓ sympathetic tone.

### Pharmacokinetics

| **Agent** | **Metabolism** | **Half-life** | **Dosing** | **Onset** |
|----|----|----|----|----|
| **Lisinopril** | Renal (unchanged) | 12–13 hrs | 10–40 mg daily | 2–4 hrs |
| **Enalapril** | Hepatic → active metabolite enalaprilat | 11 hrs | 10–40 mg daily | 1 hour |
| **Ramipril** | Hepatic → ramiprilat | 13–17 hrs | 2.5–10 mg daily | 1–2 hrs |
| **Perindopril** | Hepatic → perindoprilat | 3–10 hrs | 4–8 mg daily | 1–2 hrs |
| **Captopril** | Renal (40%), hepatic (60%) | 2–3 hrs | 25–150 mg BID-TID | 15–30 min |
| **Fosinopril** | Hepatic + renal | 12 hrs | 10–40 mg daily | 1 hour |

**Key Points:** - Lipophilic agents (ramipril, perindopril) may have superior tissue penetration - Renal excretion (lisinopril) allows accumulation in renal insufficiency - Hepatic metabolism (enalapril, fosinopril) safer in ESRD

### Renal Hemodynamic Effects

**Acute Effects (hours–days):** - ↓ Efferent arteriolar vasoconstriction → ↓ intraglomerular pressure - ↓ GFR (expected, typically 10–30% drop) - ↑ Renal plasma flow (afferent remains relatively constant) - ↓ Glomerular hyperfiltration (beneficial in proteinuria)

**Chronic Effects (weeks–months):** - ↓ Glomerulosclerosis (reduced Ang II-mediated fibrosis) - ↓ Interstitial fibrosis - ↓ Proteinuria (via hemodynamic + tubular effects) - Slowing of GFR decline in CKD

### Clinical Efficacy

**Hypertension:** - ↓ BP 8–15 mmHg systolic; effect modest, synergistic with other agents - Works best in renin-dependent hypertension (renovascular, RAS-activated states)

**Albuminuric CKD:** ACE inhibitors and ARBs lower albuminuria and can slow progression in indicated populations. [KDIGO 2024](https://pubmed.ncbi.nlm.nih.gov/38490803/) recommendations depend on albuminuria category, diabetes, and tolerability. Monitor creatinine and potassium after initiation or dose escalation; do not combine ACE inhibitor and ARB therapy.

**Heart Failure:** - **↓ Mortality 16%** (SAVE trial, post-MI LV dysfunction) - ↓ HF hospitalizations - ↓ Ventricular remodeling

**Post-MI:** - ↓ Mortality, reinfarction, HF when started early

------------------------------------------------------------------------

### Adverse Effects

#### 1. Hyperkalemia

- **Mechanism:** ↓ Aldosterone → ↓ collecting duct Na⁺-K⁺ exchange
- **Risk factors:** CKD (especially eGFR \<30), diabetes, NSAIDs, ACEi use
- **Clinical manifestation:** Asymptomatic hyperkalemia common; peaked T-waves, arrhythmias if severe
- **Management:** Measure potassium and creatinine before and within 2–4 weeks after ACE inhibitor/ARB initiation or dose increase, sooner when high risk. Review interacting drugs, intake, and reversible causes; use indicated potassium-lowering treatment. Severe or rapidly rising hyperkalemia requires prompt assessment even without symptoms or ECG changes. Reduce or hold RAAS inhibition when potassium remains uncontrolled despite treatment.

#### 2. Hypotension

- **Mechanism:** ↓ Ang II vasoconstriction
- **Risk:** Acute decompensation (sepsis, GI bleeding, diuretic excess)
- **Management:** Reduce dose; optimize intravascular volume; monitor BP at each visit

#### 3. Acute Kidney Injury (AKI)

- **Mechanism:** ↓ Efferent vasoconstriction reduces intraglomerular pressure; risky in hypotension or volume depletion
- **Presentation:** Cr rise \>30% within 1–4 weeks of initiation
- **Risk factors:** CKD (eGFR \<45), bilateral RAS, single kidney with RAS, dehydration
- **Management:** Check Cr baseline, 1 week, 2 weeks, then q3 months; expect 10–30% rise; if \>30%, review volume status, medications (NSAIDs, diuretics)

#### 4. ACE Inhibitor Cough

- **Incidence:** 15–20% (more common in females, non-smokers)
- **Mechanism:** Bradykinin accumulation in lungs
- **Onset:** 1 day to weeks
- **Character:** Dry, persistent, worse supine or at night
- **Management:** Trial off agent; if suspect ACEi → switch to ARB (no bradykinin accumulation; cough resolves in 50%–80%)
- **Note:** Cough NOT an adverse effect; does not indicate danger; discontinue if intolerable

#### 5. Angioedema

- **Incidence:** 0.1–0.5% (higher in blacks)
- **Mechanism:** Bradykinin accumulation in subcutaneous tissues
- **Presentation:** Lip, tongue, face, airway swelling; can be life-threatening
- **Timing:** Can occur months–years after initiation
- **Management:** DISCONTINUE immediately; monitor airway; consider antihistamines, steroids if mild
- **Note:** Absolute contraindication to future ACEi; ARB typically safe but carries \<10% cross-reactivity risk in angioedema

#### 6. Pregnancy Concerns

- **Teratogenicity:** ACEi contraindicated in 2nd–3rd trimester (renal dysgenesis, oligohydramnios, neonatal AKI/death)
- **1st trimester:** Relative risk; emerging data suggest possible association with cardiac anomalies; cautious use only if no alternative
- **Lactation:** Minimal transfer to breast milk; generally safe

### Contraindications and Cautions

| **Absolute Contraindication** | **Rationale** |
|----|----|
| Bilateral renal artery stenosis (RAS) | ACEi-induced AKI from ↓ efferent vasoconstriction |
| Single kidney with RAS | Same mechanism |
| Pregnancy (2nd–3rd trimester) | Teratogenicity |
| Previous ACEi-related angioedema | Absolute contraindication |
| **Relative Caution** | **Action** |
| eGFR \<30 | Monitor closely; hyperkalemia risk; reduce dose |
| K⁺ \>5.0 mmol/L | Avoid; causes further ↑ K⁺ |
| Acute decompensation/hypotension | Defer initiation; reduce dose if on agent |
| NSAIDs + ACEi (dual) | “Triple whammy” if diuretic added; AKI risk |

------------------------------------------------------------------------

## ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)

### Mechanism of Action

ARBs are **selective antagonists of AT1 receptors**, blocking Ang II action without affecting bradykinin. Result: ↓ Ang II effects WITHOUT ↑ bradykinin (hence, no cough).

**Note:** AT2 receptors (minority) promote vasodilation, anti-fibrosis; ARBs block AT1, leaving AT2 unopposed—possible additional benefit.

### Pharmacokinetics

| **Agent** | **Metabolism** | **Half-life** | **Dosing** | **Onset** |
|----|----|----|----|----|
| **Losartan** | Hepatic → active metabolite EXP3174 | 2–3 hrs | 50–100 mg daily | 1 hour |
| **Valsartan** | Minimal metabolism | 6–7 hrs | 80–320 mg daily | 1–2 hrs |
| **Irbesartan** | Minimal metabolism; hepatic (80%) | 11–15 hrs | 150–300 mg daily | 1–2 hrs |
| **Olmesartan** | Minimal metabolism | 13 hrs | 20–40 mg daily | 1–2 hrs |
| **Telmisartan** | Minimal metabolism | 24 hrs | 40–80 mg daily (longest half-life) | 1–2 hrs |
| **Candesartan** | Minimal metabolism | 9 hrs | 16–32 mg daily | 1–2 hrs |

**Key Points:** - All ARBs reach similar efficacy (no superiority demonstrated) - Telmisartan longest half-life; once-daily dosing convenient - Losartan undergoes hepatic activation to metabolite EXP3174 (more potent)

### Renal and Cardiovascular Effects

**Similarities to ACEi:** - ↓ Efferent vasoconstriction → ↓ intraglomerular pressure - ↓ Proteinuria (30–50% reduction) - ↓ GFR acutely (10–30% expected) - ↓ ESRD progression in proteinuric CKD - ↓ Mortality post-MI and in HF

**Differences from ACEi:** - NO cough (no bradykinin) - NO angioedema (rare; \<0.1% vs. ACEi 0.5%) - Equipotent BP lowering - Equipotent renal protection

### Clinical Efficacy

**Hypertension:** - ↓ BP 8–15 mmHg (similar to ACEi)

**CKD with Proteinuria:** - ↓ Proteinuria 30–50% - ↓ ESRD progression (IDNT, RENAAL trials vs. placebo in diabetic nephropathy)

**Heart Failure:** - ↓ Mortality, HF hospitalizations (CHARM, VALSARTAN trials)

**Post-MI:** - ↓ Mortality, reinfarction (similar to ACEi)

### Adverse Effects

**Hyperkalemia** (same as ACEi) - ↓ Aldosterone → ↓ K⁺ excretion - Monitor K⁺; caution with eGFR \<30, NSAIDs, other RAAS inhibitors

**Hypotension** (same as ACEi) - ↓ Ang II vasoconstriction - Risk in volume depletion, acute illness

**AKI/Creatinine Rise** (same as ACEi) - ↓ Efferent vasoconstriction - Expected 10–30% rise; monitor for \>30% rise - Caution in RAS, single kidney, dehydration

**Angioedema** (rare; \<0.1%) - Much rarer than ACEi - Mechanism unclear (not bradykinin-related) - If angioedema occurs → DO NOT switch to ACEi (cross-reactivity risk)

**Cough:** ABSENT (major advantage over ACEi)

**Hyperuricemia:** ARBs (particularly losartan) have mild uricosuric effect (losartan blocks urate reabsorption in proximal tubule)—slight ↓ in uric acid with losartan vs. other ARBs

### Contraindications

- Bilateral RAS or single kidney with RAS (AKI risk)
- Pregnancy (teratogenicity, 2nd–3rd trimester)
- K⁺ \>5.0 mmol/L
- Acute decompensation/hypotension (caution)

------------------------------------------------------------------------

## DIRECT RENIN INHIBITORS (DRI)

### Mechanism

**Aliskiren** directly binds the **active site of renin**, blocking the initial step of the RAAS cascade (renin release → angiotensinogen cleavage).

**Theoretical advantage:** More “upstream” blockade than ACEi/ARB; prevents all Ang II production.

### Pharmacokinetics

| **Property**    | **Value**                                    |
|-----------------|----------------------------------------------|
| Dose            | 150–300 mg daily                             |
| Metabolism      | Minimal (CYP3A4 substrate—drug interactions) |
| Half-life       | 24 hrs                                       |
| Onset           | 2–4 weeks (slow; accumulation)               |
| Bioavailability | 2.5% (poor; enhanced by high-fat meal)       |

### Clinical Efficacy

**Limited evidence:** - ↓ BP 8–10 mmHg (similar to ACEi/ARB) - ↓ Proteinuria (modest; less robust than ACEi/ARB) - **NO mortality benefit demonstrated** in CKD or HF (unlike ACEi/ARB)

**ALTITUDE (2012):** [Adding aliskiren to an ACE inhibitor or ARB](https://pubmed.ncbi.nlm.nih.gov/23121378/) in high-risk patients with type 2 diabetes did not improve cardiorenal outcomes and increased hyperkalemia and hypotension. Avoid this dual RAAS-blockade strategy.

### Adverse Effects

- **Hyperkalemia:** ↑ risk when combined with ACEi/ARB (see dual RAAS blockade below)
- **AKI:** Similar to ACEi/ARB; caution in volume depletion
- **Diarrhea:** 2–3% (unique to aliskiren; often reversible)
- **Cough/Angioedema:** NOT increased (unlike ACEi)

### Clinical Role

**Limited; rarely used monotherapy** due to: - Modest efficacy - No mortality benefit - Poor bioavailability - Drug interactions (CYP3A4) - Hyperkalemia risk when combined

**Specific use:** Occasionally added in resistant hypertension (as triple therapy), but ACEi/ARB preferred first-line.

------------------------------------------------------------------------

## ANGIOTENSIN II RECEPTOR-NEPRILYSIN INHIBITOR (ARNI)

### Mechanism: Sacubitril/Valsartan (Entresto)

**Dual mechanism:** 1. **Valsartan** = ARB component (Ang II blockade) 2. **Sacubitril** = Neprilysin inhibitor (↑ natriuretic peptide degradation ↓)

**Key biology:** Neprilysin breaks down natriuretic peptides (ANP, BNP, C-type NP). Inhibiting neprilysin → ↑ circulating NP levels → enhanced natriuresis, vasodilation, anti-fibrosis.

### Pharmacokinetics

| **Property** | **Value** |
|----|----|
| Dosing | Adults: commonly start 49/51 mg twice daily; use 24/26 mg twice daily when ACEi/ARB-naive, on low prior doses, or otherwise indicated. Target 97/103 mg twice daily as tolerated; allow 36 hours after an ACE inhibitor. |
| Metabolism | Hepatic metabolism of sacubitril → LBQ657 (active) |
| Half-lives | Valsartan 9–11 hrs; sacubitril metabolites 10–11 hrs |
| Onset | 2–4 weeks full effect |

### Clinical Efficacy: Heart Failure

**PARADIGM-HF Trial (2014)—Landmark:** - **Population:** ~8,400 patients with HFrEF (LVEF ≤35%) - **Primary endpoint:** CV death or HF hospitalization - **Result:** Sacubitril/valsartan ↓ primary endpoint **20% vs. enalapril** - **Mortality:** ↓ CV death 16%; ↓ all-cause death 16% - **Conclusion:** Superior to ACEi monotherapy in HFrEF

**PROVE-HF Trial (2019):** - ARNI ↓ natriuretic peptides more effectively than ACEi, suggesting superior neurohormonal modulation

### Efficacy in CKD + Proteinuria

**PIONEER Trial (2019):** - **Population:** CKD Stage 3–4 + diabetes, proteinuria - **Design:** Sacubitril/valsartan vs. losartan - **Result:** ↓ Albuminuria 36% vs. 24% with losartan (modest additional benefit) - **Renal outcomes:** Similar to losartan - **Note:** ARNI not established as superior to ARB monotherapy for renal outcomes

### Adverse Effects

**Similar to ARB + neprilysin-specific:**

| **Adverse Effect** | **Incidence/Note** |
|----|----|
| Hyperkalemia | 3–5% (PARADIGM-HF); risk with eGFR \<60 |
| Hypotension | 7–9%; more than enalapril in some trials |
| AKI/Creatinine rise | Similar to ARB; monitor Cr baseline, 1–2 weeks |
| Cough | Absent (ARB component; no bradykinin) |
| Angioedema | Rare; avoid if history of ACEi angioedema |
| **Neprilysin-specific:** |  |
| Amyloidosis risk (theoretical) | No clinical evidence in trials; neprilysin degrades amyloid-beta, but no ↑ amyloidosis observed |

### Drug Interactions

- **ACEi/ARB cannot be combined with ARNI** (dual Ang II blockade—hyperkalemia, AKI)
- **NSAIDs + ARNI:** Triple whammy if diuretic added
- **Lithium:** ↑ lithium levels (neprilysin inactivates lithium metabolism)

### Contraindications

- Bilateral RAS or single kidney RAS
- K⁺ \>5.0 mmol/L
- eGFR \<15 (caution; limited data)
- Pregnancy (2nd–3rd trimester; teratogenicity)
- History of ACEi/ARB angioedema (avoid ARNI as well)

------------------------------------------------------------------------

## NON-STEROIDAL ALDOSTERONE ANTAGONIST: FINERENONE

### Mechanism

**Finerenone** is a **non-steroidal mineralocorticoid receptor (MR) antagonist**—selective MR antagonist with reduced androgen/progesterone receptor interactions vs. spironolactone.

**Mechanism distinct from spironolactone:** - Does NOT directly inhibit aldosterone synthesis - Binds MR with **subtype selectivity** (MR over AR, PR) - Transrepressive mechanism (blocks pro-inflammatory/pro-fibrotic genes) - Anti-inflammatory, anti-fibrotic independent of Na⁺-K⁺ exchange

### Pharmacokinetics

| **Property** | **Value** |
|----|----|
| Dosing | CKD indication: eGFR 25–\<60, start 10 mg once daily; eGFR ≥60, start 20 mg once daily. Do not initiate if eGFR \<25 or potassium \>5.0 mEq/L. The CKD target is 20 mg daily, using the potassium/eGFR adjustment algorithm. |
| Metabolism | Hepatic (CYP3A4); minimal renal excretion |
| Half-life | About 2–3 hours |
| Onset | 2–4 weeks |

### Clinical Efficacy: Landmark Trials

#### FIDELIO-DKD Trial (2020)—Type 2 Diabetes + CKD

- **Population:** 5,734 adults with type 2 diabetes and albuminuric CKD were randomized; the primary analysis included 5,674. All received maximally tolerated labeled ACE inhibitor or ARB therapy.
- **Primary kidney composite:** Kidney failure, sustained eGFR decline of at least 40%, or renal death. Events occurred in 17.8% versus 21.1%; hazard ratio 0.82 over a median 2.6 years.
- **Interpretation:** This is an 18% relative reduction in the composite, not an 18–25% reduction in ESRD alone and not proof that effects of several drugs can simply be added.
- **Safety:** Hyperkalemia-related treatment discontinuation was 2.3% versus 0.9%; this is not the incidence of all hyperkalemia. [FIDELIO-DKD](https://pubmed.ncbi.nlm.nih.gov/33264825/).

#### FIGARO-DKD Trial (2021)—T2DM + CKD Stages 2–3

- **Population:** 7,437 adults with type 2 diabetes and a broader spectrum of albuminuric CKD were randomized on maximally tolerated RAAS blockade.
- **Primary cardiovascular composite:** Cardiovascular death, nonfatal MI, nonfatal stroke, or heart-failure hospitalization occurred in 12.4% versus 14.2%; hazard ratio 0.87, driven mainly by fewer heart-failure hospitalizations.
- **Kidney outcome:** The secondary kidney composite hazard ratio was 0.87 (95% CI 0.76–1.01); do not describe every component as showing a proven 18% benefit. [FIGARO-DKD](https://pubmed.ncbi.nlm.nih.gov/34449181/).

### Proposed Renal Mechanisms Beyond Aldosterone

1.  **Transrepression:** Blocks MR-mediated inflammation, reduces IL-6, TNF-α
2.  **Anti-fibrotic:** ↓ TGF-β signaling, ↓ myofibroblast activation
3.  **Endothelial:** ↑ nitric oxide, ↓ oxidative stress
4.  **Podocyte:** ↓ proteinuria via reduced foot process effacement
5.  **Glomerular:** ↓ SGLT1 expression (possible glucose-related protection)

### Adverse Effects

**Hyperkalemia:** Check potassium and eGFR before initiation, at 4 weeks after starting or changing dose, and periodically thereafter; check sooner with higher risk. In CKD, do not initiate if potassium \>5.0 mEq/L. At \>4.8–5.0, initiation may be considered with additional monitoring within the first 4 weeks.

**CKD continuation algorithm:** At potassium \>4.8–5.5, maintain the current 10 or 20 mg dose. If potassium \>5.5, withhold; restart at 10 mg once potassium is ≤5.0. At potassium ≤4.8, a 10 mg dose may be increased to 20 mg unless eGFR fell by more than 30%. Do not confuse continuation criteria with entry criteria.

**Other labeled adverse reactions:** Hypotension and hyponatremia. Monitor BP and sodium when clinically indicated, and review kidney function and interacting medicines.

**Indication matters:** The above is the CKD dose-adjustment algorithm. Heart failure with LVEF ≥40% has separate target-dose and potassium adjustment instructions. [Current prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c).

### Contraindications and Cautions

| **Contraindication** | **Rationale** |
|----|----|
| K⁺ \>5.0 mEq/L at baseline: do not initiate | Hyperkalemia risk |
| eGFR \<25 mL/min/1.73 m²: initiation not recommended | Use labeled kidney-function entry criteria |
| Strong CYP3A4 inhibitor use or adrenal insufficiency | Contraindicated by current labeling |
| **Caution** |  |
| eGFR 25–30 | Monitor K⁺ closely; may need dose adjustment |
| ACEi/ARB + NSAIDs (triple) | Triple whammy—AKI, hyperkalemia risk |
| Spironolactone co-use | Additive K⁺ rise; avoid dual MRA therapy |

### Clinical Role and Integration

**KDIGO diabetes/CKD guidance:** Consider finerenone for eligible adults with type 2 diabetes, eGFR above 25 mL/min/1.73 m², normal potassium, and persistent albuminuria despite a maximally tolerated ACE inhibitor or ARB. It complements appropriate RAAS blockade rather than replacing it. [KDIGO 2024](https://pubmed.ncbi.nlm.nih.gov/38490803/).

**Sequence eligible therapies:** Use a single maximally tolerated ACE inhibitor or ARB when indicated, and add an SGLT2 inhibitor for an appropriate CKD indication. In type 2 diabetes with persistent albuminuria, finerenone may be added when eGFR is at least 25 and potassium is no higher than 5.0 mEq/L, with closer early monitoring at 4.8–5.0. Select a GLP-1 receptor agonist for its diabetes, cardiovascular, kidney, or weight indication. Cross-trial relative benefits cannot simply be summed.

------------------------------------------------------------------------

## DUAL AND TRIPLE RAAS BLOCKADE: Why It Failed

### Historical Context: Rationale for Dual Blockade

- **Concept:** Block RAAS at multiple points → greater neurohormonal suppression → better renal protection
- **Theoretical basis:** ACEi ↓ Ang II but ↑ renin (compensatory); ARB ↓ Ang II but ↑ renin; combination = maximal Ang II suppression
- **1990s–2000s enthusiasm:** Multiple small studies suggested dual blockade benefit

### Major Clinical Trials: Null Results

#### VA NEPHRON-D Trial (2014)

- **Population:** ~1,448 veterans with CKD Stage 3–4 + hypertension
- **Intervention:** Losartan monotherapy vs. losartan + lisinopril
- **Results:**
  - NO difference in primary endpoint (GFR decline)
  - ↑ Hyperkalemia: 5.0% (dual) vs. 2.6% (mono)
  - ↑ AKI: 1.3% (dual) vs. 0.6% (mono)
- **Conclusion:** Dual RAAS blockade = hyperkalemia + AKI **without renal benefit**

#### ONTARGET Trial (2008)—Post-MI, High CV Risk

- **Population:** ~25,620 patients with prior MI, stroke, or high CV risk
- **Intervention:** Ramipril monotherapy vs. valsartan monotherapy vs. ramipril + valsartan
- **Results:**
  - **Dual therapy did NOT improve CV outcomes** vs. monotherapy
  - ↑ Renal dysfunction: 13.5% (dual) vs. 10.2–11.6% (mono)
  - ↑ Hyperkalemia: 4.2% (dual) vs. 1.7% (ramipril alone)
  - ↑ Syncope: 0.3% (dual) vs. 0.1% (mono)
- **Conclusion:** ACEi + ARB = harm (↑ AKI, hyperkalemia, syncope) without benefit

#### ACCOMPLISH Trial (2008)—Hypertension

- **Population:** ~11,506 with hypertension + high CV risk
- **Intervention:** Benazepril/amlodipine vs. benazepril/HCTZ
- **Note:** Not true dual RAAS blockade, but ACEi + diuretic vs. ACEi monotherapy
- **Result:** ACEi/amlodipine superior to ACEi/HCTZ (supporting RAAS-sparing diuretics)

### Mechanisms of Dual RAAS Blockade Failure

1.  **Hyperkalemia:** Sequential ↓ aldosterone → severe K⁺ retention
2.  **AKI:** Efferent vasoconstriction from dual ↓ Ang II + volume depletion risk
3.  **Counter-regulatory activation:** Renin ↑ dramatically with dual blockade (feedback loop); breakthrough Ang II production possible
4.  **Glomerular hemodynamic collapse:** Too much efferent vasodilation → loss of driving pressure for filtration
5.  **Blunted efficacy:** Physiologic adaptation/escape (aldosterone escape phenomenon observed in some dual-therapy patients)

### Current Consensus

**Guidelines unanimously recommend:** - **Monotherapy** with ACEi OR ARB (NOT both) - **Exception:** ARNI (sacubitril/valsartan) = ARB + neprilysin inhibitor (different mechanism—valsartan component within ARNI is permissible) - **Addition of finerenone:** OK with ACEi/ARB monotherapy (non-overlapping mechanism)

------------------------------------------------------------------------

## MONITORING AND MANAGEMENT DURING RAAS INHIBITION

### Baseline Assessment (Pre-Initiation)

| **Parameter**        | **Action**                                    |
|----------------------|-----------------------------------------------|
| **Renal function**   | Baseline eGFR, Cr                             |
| **Potassium**        | Baseline K⁺ (defer if K⁺ \>5.0)               |
| **Blood pressure**   | Baseline BP; assess volume status             |
| **Pregnancy status** | Confirm not pregnant (2nd–3rd trimester risk) |
| **Medications**      | Review NSAIDs, diuretics, other RAAS agents   |
| **History**          | Prior ACEi angioedema? RAS? Kidney disease?   |

### Post-Initiation Monitoring

**First 1–2 weeks:** - **Cr + eGFR:** Check at 1 week; expect 10–30% rise - **K⁺:** Check at 1 week; expect modest ↑ - **BP:** Monitor for hypotension - **Symptoms:** Dizziness, syncope, hyperkalemia signs (palpitations, weakness)

**Weeks 2–8:** - **Cr + eGFR:** Check again at 2 weeks if initial rise \>30% - **K⁺:** Check at 2 weeks if on diuretic or eGFR \<45 - **BP:** Titrate dose to target

**Months 2–3 onward:** - **Cr, eGFR, K⁺:** Every 3 months × 1 year, then annually if stable - **More frequent monitoring (monthly) if:** - eGFR \<45 - K⁺ at upper limit of normal - Recent dose escalation - Concurrent NSAIDs or diuretics

### Interpretation of Creatinine Rise

| **Cr Rise** | **Timing** | **Interpretation** | **Action** |
|----|----|----|----|
| 10–30% | 1–2 weeks | Expected; reflects ↓ intraglomerular pressure | Continue agent; recheck in 2 weeks |
| \>30% (but \<50%) | 1–4 weeks | May be pre-renal or hemodynamic | Review volume status, BP, diuretics; recheck Cr; if stable, continue |
| \>50% or progressive | Ongoing | Suggests pre-renal (volume depletion, hypotension) or AKI | STOP agent; evaluate for RAS, dehydration; recheck Cr in 1 week |

### When to Hold or Discontinue RAAS Inhibitors

| **Scenario** | **Action** |
|----|----|
| **Severe, rapidly rising, or uncontrolled hyperkalemia (symptoms may be absent)** | HOLD; treat hyperkalemia |
| **Cr rise \>50% from baseline** | HOLD; investigate pre-renal causes |
| **Symptomatic hypotension** | HOLD; reassess intravascular volume |
| **Angioedema (ACEi)** | Stop the ACE inhibitor permanently and assess the airway urgently. A carefully selected ARB may be considered after individualized risk discussion; sacubitril/valsartan is contraindicated with prior ACEi/ARB-related angioedema. |
| **Persistent dry cough (ACEi)** | DISCONTINUE; consider ARB if intolerable |
| **Acute illness (sepsis, GI bleed)** | Temporarily HOLD; restart when stable |
| **Planned contrast study** | HOLD day of procedure (especially if eGFR \<45) |
| **Pregnancy planned or confirmed** | DISCONTINUE (1st trim caution; 2nd–3rd trim contraindicated) |

------------------------------------------------------------------------

## Clinical Scenarios

### Scenario 1: CKD Stage 3b + Type 2 Diabetes + Proteinuria

**Clinical:** 58-year-old male with T2DM, BP 145/92, eGFR 38, uACR 180 mg/g (overt albuminuria), on metformin monotherapy, no current antihypertensive.

**Labs:** - Cr 1.6 mg/dL - K⁺ 4.3 mmol/L - Urine dip: 2+ protein

**Plan:** 1. **Start ACEi (lisinopril 10 mg daily) or ARB (losartan 50 mg daily)** - Both equipotent for proteinuria reduction and renal protection - Lisinopril slightly cheaper; losartan if cough develops 2. **Check Cr + K⁺ at 1 week** - Expect Cr ↑ 10–30% (acceptable) - K⁺ should remain \<5.0 3. **Goal BP:** \<130/80 (2025 AHA/ACC, ADA Standards of Care). KDIGO 2021 suggests systolic \<120 when tolerated, using standardized office measurement (grade 2B, driven by the CKD subgroup of SPRINT); it excludes transplant recipients and dialysis patients. Much of the gap is measurement technique rather than disagreement about physiology — KDIGO’s lower number presumes a standardized or unattended reading, which most routine clinic cuffs do not meet. 4. **Add SGLT2i (dapagliflozin 10 mg daily)** - ↓ ESRD progression, CV death - Continue metformin 5. **Lifestyle:** Sodium restriction \<3 g/day, weight loss if overweight 6. **3-month reassess:** Recheck eGFR, K⁺, proteinuria; if stable and K⁺ \<5.0, consider adding finerenone 10 mg daily 7. **Target:** CKD stabilization, ↓ proteinuria, BP control

------------------------------------------------------------------------

### Scenario 2: Heart Failure with Reduced EF + Diabetes

**Clinical:** 62-year-old female with HFrEF (LVEF 28%), hypertension, T2DM, on carvedilol 25 mg BID.

**Presentation:** Dyspnea on exertion, 2+ lower extremity edema.

**Labs:** - Cr 1.3 mg/dL (eGFR 48) - K⁺ 4.5 mmol/L - BNP 650 pg/mL

**Plan:** 1. **Start an indicated ACE inhibitor or, preferably when suitable, ARNI; because this patient is not taking an ACE inhibitor or ARB, use sacubitril/valsartan 24/26 mg twice daily initially** - ARNI preferred in HFrEF (PARADIGM-HF 20% mortality reduction) - If cost/access issue, ACEi acceptable - Do NOT start both ACEi and ARB (dual blockade) 2. **Verify not on NSAIDs or diuretics causing volume depletion** 3. **Check Cr + K⁺ at 1 week** - Expected Cr ↑ 10–30% - K⁺ should remain \<5.5 4. **Titrate to target dose:** - ARNI: Escalate to 97/103 mg BID (if tolerated) - If using lisinopril, titrate according to the heart-failure regimen and tolerance 5. **Add beta-blocker** (carvedilol already on board) + **aldosterone antagonist** (spironolactone 25 mg daily or eplerenone 25 mg daily) - RALES trial: ↓ mortality 30% with spironolactone in HF - Start a steroidal MRA only if eGFR \>30 and K⁺ \<5.0; monitor closely and reassess/stop if potassium cannot be maintained \<5.5 6. **Diuretics:** If volume-overloaded, add furosemide (separate handout); do NOT defer diuretics to start RAAS inhibitors 7. **SGLT2i:** Add dapagliflozin 10 mg daily (↓ HF hospitalization) 8. **3-month reassess:** BNP, Cr, K⁺, weight, EF (echo); adjust doses

------------------------------------------------------------------------

### Scenario 3: Dual RAAS Blockade (Incorrect) to Monotherapy (Correct)

**Clinical:** 72-year-old male with CKD Stage 4 (eGFR 22) referred on losartan 100 mg daily + lisinopril 10 mg daily (prescribed by cardiologist post-MI).

**Recent labs:** - K⁺ 5.7 mmol/L (elevated) - Cr 2.8 mg/dL (Cr baseline pre-MI was 2.0; rise ↑0.8 in 3 months) - BP 128/76 (well-controlled)

**Recognize:** Dual RAAS blockade causing hyperkalemia + AKI

**Plan:** Stop dual ACE inhibitor/ARB treatment and promptly reassess the potassium result, ECG when indicated, creatinine trend, volume status, and interacting medicines. K⁺ 5.7 with worsening kidney function needs a timely potassium-management plan, not an automatic one-week wait. Decide whether one RAAS blocker can be continued or temporarily held according to the response. Do not add eplerenone as a workaround in this patient with eGFR 22 and hyperkalemia. Optimize other indicated post-MI/HF therapy, and document repeat testing and responsibility for reassessment.

------------------------------------------------------------------------

## Practice Questions

### Question 1

A 52-year-old woman with CKD Stage 3a (eGFR 56) and hypertension (BP 162/98) is started on lisinopril 10 mg daily. After 1 week, she develops a persistent dry cough and her serum creatinine has risen from 1.0 to 1.15 mg/dL. K⁺ is 4.6 mmol/L.

Which of the following is the MOST appropriate next step?

1.  Continue lisinopril; cough is expected and will resolve
2.  Increase lisinopril to 20 mg daily to improve BP control
3.  Switch to losartan 50 mg daily for ACEi cough
4.  Discontinue lisinopril and start amlodipine 5 mg daily
5.  Add spironolactone 25 mg daily for additional BP control

**Answer:** C (switch to ARB; cough resolves in 50–80%)

**Rationale:** - ACEi cough affects 15–20% of patients; related to bradykinin accumulation in lungs - Cough NOT dangerous but intolerable if persistent - ARB substitution resolves cough in majority (no bradykinin effect) - Cr rise 10–30% expected (acceptable); K⁺ stable - Continue monitoring Cr; expect stabilization in 2–4 weeks - Amlodipine suitable alternative if ARB cough develops (rare)

------------------------------------------------------------------------

### Question 2

A 65-year-old male with LVEF 32%, CKD Stage 4 (eGFR 28), and hypertension is on lisinopril 10 mg daily and carvedilol 25 mg BID. He is referred for worsening dyspnea. Labs show K⁺ 5.8 mmol/L, Cr 1.9 mg/dL (baseline 1.7), BNP 750 pg/mL.

Which of the following represents the BEST next management step?

1.  Increase lisinopril to 20 mg daily for additional neurohormonal suppression
2.  Add eplerenone 25 mg daily for aldosterone antagonism
3.  Add spironolactone 25 mg daily and monitor K⁺ closely
4.  Promptly reassess potassium, ECG/clinical urgency, volume status, and contributing medicines; treat hyperkalemia and congestion as indicated before changing long-term RAAS therapy
5.  Add furosemide 40 mg daily without reassessing potassium, volume status, or RAAS therapy

**Answer:** D. First address the current hyperkalemia and possible decompensated heart failure; an immediate ACE inhibitor-to-ARNI switch is not a potassium-lowering strategy.

**Rationale:** K⁺ 5.8 with CKD and worsening dyspnea calls for prompt confirmation/trajectory assessment, ECG and clinical assessment, and review of potassium supplements, NSAIDs, other interacting drugs, and congestion. Do not let a normal ECG or lack of symptoms exclude important hyperkalemia. Treat according to severity and determine whether lisinopril needs temporary withholding; do not increase its dose now. Loop diuretics can improve congestion and increase urinary potassium excretion when kidney response permits, but do not replace urgent hyperkalemia treatment when indicated. Avoid starting spironolactone/eplerenone here: eGFR is ≤30 and potassium is ≥5.0, so simply correcting potassium would not remove the kidney-function limitation.

**Later ARNI decision:** Once clinically stable with acceptable potassium, assess whether sacubitril/valsartan is appropriate for HFrEF. It still contains an ARB and can cause hyperkalemia. If switching from lisinopril, allow at least 36 hours before the first ARNI dose; with eGFR \<30, the labeled starting dose is 24/26 mg twice daily, followed by BP, potassium, and kidney-function monitoring and titration as tolerated. Prior ACE inhibitor/ARB-related angioedema is a contraindication. [ENTRESTO prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=000dc81d-ab91-450c-8eae-8eb74e72296f); [2022 AHA/ACC/HFSA heart-failure guideline](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063).

------------------------------------------------------------------------

### Question 3

A 48-year-old male with Type 2 diabetes, hypertension, CKD Stage 3b (eGFR 42), and overt albuminuria (uACR 220 mg/g) is on metformin and lisinopril 20 mg daily. His BP is 138/86 and his recent K⁺ is 4.9 mmol/L. His cardiologist recommends adding losartan 50 mg daily for additional renal protection.

Which of the following is the MOST appropriate response?

1.  Agree with cardiologist; dual RAAS blockade provides additional renal benefit
2.  Agree, but reduce lisinopril to 10 mg daily and start losartan 50 mg daily
3.  Disagree; consider finerenone 10 mg daily after confirming persistent albuminuria on maximally tolerated ACE inhibition, with additional early potassium monitoring at K⁺ 4.9
4.  Disagree; instead, add SGLT2 inhibitor (dapagliflozin) and continue lisinopril
5.  Both C and D are correct

**Answer:** E, provided each option’s eligibility and monitoring conditions are met. Avoid adding an ARB to an ACE inhibitor; the alternatives are eligible SGLT2 therapy and carefully monitored finerenone.

**Rationale:** Dual ACE inhibitor/ARB therapy increases AKI and hyperkalemia without added kidney benefit. Confirm lisinopril is at the maximum tolerated dose and add indicated SGLT2 therapy. With eGFR 42 and persistent albuminuria, finerenone 10 mg may be considered, but K⁺ 4.9 requires additional monitoring within the first 4 weeks; potassium above 5.0 would preclude initiation. Recheck potassium at 4 weeks after initiation or dose adjustment. Withhold finerenone if potassium exceeds 5.5 and restart at 10 mg only once it is ≤5.0. FIDELIO’s 18% result applies to its composite kidney outcome, not ESRD alone.

------------------------------------------------------------------------

## Clinical Pearl Summary

1.  **RAAS physiology:** Ang II drives efferent vasoconstriction (↑ intraglomerular pressure) and aldosterone-mediated Na⁺ retention; RAAS inhibitors relieve both.

2.  **ACEi mechanism:** ↓ Ang II + ↑ bradykinin → cough (15–20%), angioedema (0.5%), but excellent renoprotection and mortality benefit.

3.  **ARB mechanism:** ↓ Ang II WITHOUT bradykinin → no cough, rare angioedema, equipotent renoprotection vs. ACEi.

4.  **Renal effects common to ACEi/ARB:** ↓ Efferent vasoconstriction → ↓ intraglomerular pressure → ↓ proteinuria 30–50% + ↓ ESRD progression.

5.  **Expected Cr rise 10–30% after ACEi/ARB initiation** is acceptable; reflects hemodynamic adaptation, not nephrotoxicity.

6.  **Hyperkalemia:** Most significant adverse effect; risk ↑ with eGFR \<30, NSAIDs, concurrent K⁺-sparing agents, diabetes.

7.  **Dual RAAS blockade failed in major trials** (VA NEPHRON-D, ONTARGET)—hyperkalemia, AKI, NO benefit. Monotherapy only.

8.  **ARNI (sacubitril/valsartan):** Superior to ACEi in HFrEF (PARADIGM-HF 20% mortality reduction); ↓ proteinuria in CKD but not established as superior to ARB monotherapy for renal outcomes.

9.  **Finerenone:** In eligible type 2 diabetic CKD, reduces kidney and cardiovascular composite outcomes on top of ACE inhibitor or ARB treatment. Do not relabel composite results as an ESRD-only benefit; monitor for hyperkalemia.

10. **Eligibility before combination:** Use ACE inhibitor or ARB monotherapy and indicated SGLT2 therapy. For finerenone in CKD, verify the indication, eGFR ≥25, and potassium ≤5.0 before starting; check potassium at 4 weeks and earlier if high risk. Continuation at potassium up to 5.5 is a different decision from initiation.

------------------------------------------------------------------------

## References

1.  Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38490803/)

2.  McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25176015/)

3.  Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892-1903. [PubMed](https://pubmed.ncbi.nlm.nih.gov/24206457/)

4.  Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-553. [PubMed](https://pubmed.ncbi.nlm.nih.gov/18707986/)

5.  Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33264825/)

6.  Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34449181/)

7.  Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-1462. [PubMed](https://pubmed.ncbi.nlm.nih.gov/8413456/)

8.  Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387-395. [PubMed](https://pubmed.ncbi.nlm.nih.gov/9691107/)

9.  Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669-677. [PubMed](https://pubmed.ncbi.nlm.nih.gov/1386652/)

10. **Lexicomp, UpToDate, Micromedex** — Drug information, dosing, adverse effects, interactions (subscription-based resources).

------------------------------------------------------------------------

## See Also

### Related Student Handouts

- Diuretics
- Immunosuppressive Therapy in Nephrology
- CKD Overview and Classification
- Diabetic Kidney Disease
- Hypertension Management
- GDMT: Four Pillars of Therapy
- SGLT2 Inhibitors in Kidney Disease

### Clinical Content (01-Clinical-Medicine/Nephrology)

- Essential Renal Laboratory Tests
- Hypertension Management Hub
- CKD Hub - Full Clinical Reference
- Cardio-Renal Ecosystem Hub

### Atomic Notes (ZK)

- RAAS System and Blood Pressure Regulation

### Butler-COM Resources

- Butler COM - Nephrology Deep Dive
- Butler COM - Heart Failure GDMT Deep Dive

------------------------------------------------------------------------

**Created:** 2026-02-12 **Last Updated:** 2026-02-12 **Suggested Citation:** “Renal Pharmacology: RAAS Inhibitors and Renoprotective Therapy.” Medical Education Handout, 2026.

## Clinical Resources

- Clinical Review: Lab Perspective Ldh And Bicarb — Comprehensive clinical review with PubMed references
- Clinical Review: Clincial Perspective Bicarb And Ldh — Comprehensive clinical review with PubMed references
- Clinical Review: Raasi Summary — Comprehensive clinical review with PubMed references
- Clinical Review: Sodium Bicarbonate Document — Comprehensive clinical review with PubMed references


---

[Website version](https://urinenephrology.org/student-resources/pharmacology/raas-inhibitors-student-handout.html) · Markdown synchronized October 3, 2026.